|
gptkbp:instanceOf
|
gptkb:drug
small molecule
|
|
gptkbp:approvalYear
|
2021
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EG02
|
|
gptkbp:brand
|
gptkb:Lumakras
gptkb:Lumykras
|
|
gptkbp:CASNumber
|
2296729-00-3
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:developer
|
gptkb:Amgen
|
|
gptkbp:eliminationHalfLife
|
5.5 hours
|
|
gptkbp:hasMolecularFormula
|
C30H30F2N6O3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sotorasib
|
|
gptkbp:indication
|
KRAS G12C-mutated locally advanced or metastatic NSCLC
|
|
gptkbp:KEGGID
|
D12077
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
KRAS G12C inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:proteinBinding
|
89%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL4297599
gptkb:DB16335
121694644
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
fatigue
hepatotoxicity
|
|
gptkbp:synonym
|
gptkb:AMG_510
|
|
gptkbp:target
|
KRAS G12C mutation
|
|
gptkbp:UNII
|
1X8A2V8A7U
|
|
gptkbp:usedFor
|
treatment of non-small cell lung cancer
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|